MedTrace Logo

Hip-Fracture Surgery on Patients in Clopidogrel Therapy

NCT02391883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 356

Last updated 2015-03-18

No results posted yet for this study

Summary

Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major blood loss during and after surgery, or putting the patient at risk of a thromboembolic event after surgery. The investigators hypothesize that the risk of a major blood loss in patients that are still under the effect of Clopidogrel or DAPT during or after hip-fracture surgery is relatively low. The investigators have conducted a retrospective observational study on hip-fracture patients to test this hypothesis.

Conditions

  • Hip Fracture

Interventions

DRUG

Clopidogrel

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-12-31
Completion
2015-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02391883 on ClinicalTrials.gov